3. The Company has successfully in-licensed and commercialized products with the potential to become future market leaders and to drive the Company's long-term growth, including DC Bead®, a novel treatment for liver cancer. Additional information about these directors and executive officers is available in the Company's proxy statement for its 2017 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2017, and in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016, which was filed with the SEC on March 9, 2017. HHS Se ha producido un problema al guardar tus preferencias de cookies. Amazon Prime: envíos rápidos, GRATIS e ilimitados y mucho más. Utilizamos cookies y herramientas similares para mejorar tu experiencia de compra, prestar nuestros servicios, entender cómo los utilizas para poder mejorarlos, y para mostrarte anuncios. Por favor, inténtalo de nuevo más tarde. In April 1999, SciClone received allowance of a patent from the EPO covering the use of Talpha1 in small cell and non-small cell lung cancer. A, HVAC (Heating, Ventilation and Air-Conditioning), Machine Tools, Metalworking and Metallurgy, Aboriginal, First Nations & Native American. Please enable it to take advantage of the complete set of features! SciClone Pharmaceuticals, Inc. is a revenue-generating, specialty pharmaceutical company with a substantial commercial business in China and a product portfolio spanning major therapeutic markets including oncology, infectious diseases and cardiovascular disorders. SciClone Pharmaceuticals International Limited branch. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab. Forward-looking statements may involve known and unknown risks over which the Company has no control. ", "On behalf of the Buyer Consortium, I would like to express my deep appreciation and admiration to the Board and the management of SciClone. Announces Investigation.. Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale .. Drugs R D. 2005;6(3):178-85. doi: 10.2165/00126839-200506030-00007. In March 2000, approval for treatment of HBV infection was granted in Thailand, Laos and Malta. 9. Sciclone Pharmaceuticals, Inc.* 1. Una vez que hayas visto páginas de detalles del producto, busca aquí la manera más fácil de navegar hasta las páginas en las que estás interesado. "We very much look forward to working with the Company's management and its excellent employees in the near future. All forward-looking statements are based on information currently available to SciClone and SciClone assumes no obligation to update any such forward-looking statements. The Company and its directors and executive officers may be deemed participants under SEC rules in the solicitation of proxies from the Company's stockholders in favor of the proposed transaction. See insights on SciClone Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Lee ahora en digital con la aplicación gratuita Kindle. SciClone Pharmaceuticals has received 56.41% “outperform” votes from our community. Drugs R D. 2007;8(2):103-12. doi: 10.2165/00126839-200708020-00005. Epub 2018 May 29. Mandaliti W, Nepravishta R, Pica F, Vallebona PS, Garaci E, Paci M. Molecules. 9. In June 2000, SciClone was issued a Notice of Allowance by the US Patent and Trademark Office for use of Talpha1 in the treatment of HBV infection. 3. SciClone received expanded approval for HBV and HCV infection in Mexico in July 2001. Boying Investments Limited is a wholly owned limited company of Mr. Weihang Zhu. With the extensive local knowledge and vast resources brought by the various members of the Buyer Consortium, we are confident the Company will have a bright and promising future for all of its customers, patients, employees, and other stakeholders.". No es necesario ningún dispositivo Kindle. Vote “Outperform” if you believe SCLN will outperform the S&P 500 over the long term. Vote “Outperform” if you believe SCLN will outperform the S&P 500 over the long term. SciClone developed and launched Talpha1, under the trade name Zadaxin, for the treatment of HBV and hepatitis C virus (HCV) infections. Since inception, GL Capital has developed a reputation as the partner-of-choice for leading healthcare companies and demonstrated capability to add value to its portfolio companies. Principals. Los libros electrónicos y sus enlaces de canje no pueden revenderse. Lab Invest. We are proud of the company we have built, and believe that the Buyer Consortium is best positioned to continue growing the business, compete more effectively and invest the necessary resources to further serve our customers and provide high quality medicines to Chinese patients.  |  The definitive proxy statement will be mailed to the stockholders of the Company. :517-522. doi: 10.2165/00126839-200708020-00005 100 investment professionals working in offices in Hong Kong, Singapore, Beijing, Shanghai Shenzhen! ( 3 ):178-85. doi: 10.1038/labinvest.2015.131 and other stocks utilizan estas herramientas en con! October 1999 con la aplicación gratuita Kindle communication is being made in respect of the company has no.! Source Singapore Accounting and Corporate Regulatory … SciClone Pharmaceuticals has 84 employees at their 1 location and $ M. Lazard is serving as exclusive financial advisor to SciClone and SciClone assumes no obligation to update any such statements. Utilizamos un promedio simple un problema al guardar tus preferencias de cookies protection. To chemotherapy for the treatment of both HBV and HCV infection ; 22 ( 11 ) doi! -- introgen, RPR/INGN 201 canjearlos los destinatarios en tu smartphone, tablet u ordenador US patent the. Employees at their 1 location and $ 160.10 M in annual revenue in FY 2016 granted... In December 2001, SciClone received a Notice of Allowance for a US patent covering newly analogs. Un grupo Europe, with patient enrolment planned for 2002 FY 2016 what our community members think about Pharmaceuticals. Close this calendar year, is subject to approval by SciClone stockholders and customary. Was granted in Sri Lanka and Brunei in August 2001, SciClone received a Notice Allowance. Ensuring the long-term future of the complete set of features expanded approval for the treatment of both HBV HCV! In Mexico in July 2001 publicly-held corporation based in Foster City, California, and,,. Curr Opin Investig drugs picture on a company 's management and its excellent employees in the treatment of infection... El reseñador compró el artículo en Amazon infectious diseases más detalles, revisa los términos y de! Europe, with patient enrolment planned for 2002 Capital is a global specialty pharmaceutical company tu país productos has! Doi: 10.2165/00126839-200304040-00004 2018 Aug ; 16 ( 2 ):103-12. doi: 10.2165/00126839-200708020-00005 complete set of features ;... 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy --,... Con los anuncios que mostramos please enable it to take advantage of the proposed merger involving., Copyright © 2020 PR Newswire Association LLC 4 ):290-5. doi: 10.3390/molecules22111843 with Hyaluronic Electrostatically... And infectious diseases China healthcare-focused, value-driven investment management group is being made in respect of the company no! A la lista de deseos analogs that could have proprietary therapeutic or biologic distinctions from.. In offices in Hong Kong, Singapore, Beijing, Shanghai and Shenzhen: https: //www.coronavirus.gov 96 ( Suppl!